

**Anthony J. Cavalieri** has joined the board of directors of Chromatin (Chicago). He spent more than 20 years at Pioneer Hi-Bred International, a subsidiary of DuPont, and recently retired as vice president in charge of trait and technology development.

Affymax (Palo Alto, CA, USA) has added to its management team, appointing **Douglas L. Cole** as vice president of development and **Julie S. Iwashita** as director of clinical development. Dr. Cole joins Affymax from Isis Pharmaceuticals, where he was vice president, technical development. Ms. Iwashita served most recently as project manager, medical affairs at Genitope, and previously worked at Amgen as assistant manager, clinical affairs. Affymax plans to begin clinical trials later this year with Hematide, a peptide that stimulates red blood cell production.

Compound Therapeutics (Waltham, MA, USA) has named **Alan Crane** to its board of directors. Mr. Crane is CEO of Momenta Pharmaceuticals and a partner at Polaris Ventures. In addition, the company announced that existing board member **L. Patrick Gage**, formerly president of Wyeth Research, will serve as executive chairman.

Advancis Pharmaceutical (Germantown, MD, USA) has announced the appointment of **Barry Hafkin** as chief scientific officer. Dr. Hafkin was most recently director of virology and immunology for Boehringer Ingelheim Pharmaceuticals.

**Donald S. Kaplan** has been appointed president and chief operating officer of Protein Polymer Technologies (San Diego, CA, USA). **J. Thomas Parmeter** will remain chairman and CEO. Dr. Kaplan has directed product development for the company's surgical adhesive and sealant program since April 2003. Previously, he was senior vice president, operations and technology, at US Surgical Corp.



BioMedicines (Emeryville, CA, USA) has appointed **K. Alice Leung** as president and CEO. Ms. Leung was previously vice president and general manager of the oncology business unit at Berlex

Laboratories, the US affiliate of Schering.

Cylene Pharmaceuticals (San Diego, CA, USA) has named **John K.C. Lim** as vice president of clinical operations. Dr. Lim joins the company from US Oncology Research, where he was vice

president for research operations. Before joining US Oncology, he held senior operations positions at Covance and Quintiles.

Venture capital group Abingworth Management (London) has appointed **Genghis Lloyd-Harris** to its team. Dr. Lloyd-Harris was formerly a managing director of Credit Suisse First Boston, serving in the European equity research group.

**Frank Morich** has been elected to the board of directors of Innate Pharma (Marseille, France). Dr. Morich previously served on the boards of Bayer AG and Bayer Corp. and as chairman of the board for Bayer Healthcare AG. He is currently CEO of AM Pharma.



Peter O'Hanley

**Peter D. O'Hanley** has been appointed senior vice president of clinical development and regulatory affairs at AVI BioPharma (Portland, OR, USA). He previously served as vice president of clinical development at Maxygen. In addition, AVI BioPharma has named **R. Ray Cummings** vice president of business development. Mr. Cummings is the founder of Cummings Consulting, and was previously vice president of business development at Aradigm.

**Mark A. Philip** has been named president of Stryker Biotech (Kalamazoo, MI, USA). Mr. Philip had served as president and CEO of Zycos since 1997.

**Raymond J. Tesi** has joined Cellera Therapeutics (Palo Alto, CA, USA) as executive vice president of clinical development and medical affairs. Dr. Tesi was formerly senior vice president of clinical development and medical affairs at SangStat.

Ganymed Pharmaceuticals (Mainz, Germany) has announced that **Rainer Wessel** has been appointed president and CEO, succeeding interim CEO **James A. Ratigan**. Dr. Wessel most recently served as president and CEO of Axxima Pharmaceuticals.

Corgentech (S. San Francisco, CA, USA) has named **Thomas Yonker** vice president of project and alliance management. Mr. Yonker previously served as project management director for InterMune. In addition, Corgentech appointed **Nancy Donahue** as vice president of cardiovascular marketing. Ms. Donahue worked for 15 years in sales and marketing for GlaxoSmithKline.